Here’s how Johnson & Johnson has treated more than 10,000 patients and counting with this cutting-edge therapy. The print and digital publications we produce each year that recap the company’s …

Johnson & Johnson and its subsidiaries (the Company) have approximately 132,200 employees worldwide engaged in the research and development, manufacture and sale of a broad range of …

We would like to show you a description here but the site won’t allow us.

We received approval for a subcutaneous formulation of multiple myeloma drug DARZALEX® (daratumumab) in 2020—ahead of our scheduled U.S. PDUFA date. This new formulation took a …

About us Our company Medicines & therapies Medical devices & technology Careers Investors Media Key links Terms of use Privacy statement Cookie policy Customize cookie settings Get in touch …

Jan 26, 2021 · New Brunswick, N.J. (January 26, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020.

Johnson & Johnson does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Jan 12, 2026 · Copies of these filings are available online at www.sec.gov, on this Internet site (www.investor.jnj.com) under “Financials—SEC Filings,” or on request from Johnson & Johnson.

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated and cured, treatments are …

Dec 29, 2024 · This Annual Report on Form 10-K and Johnson & Johnson’s other publicly available documents contain “forward-looking statements” within the meaning of the safe harbor provisions of …